July 24, 2017 - Orgenesis, Inc. (NASDAQ:ORGS) has filed a financial statement reporting Weighted Average Number Of Diluted Shares Outstanding of $9,568,413 USD. Previously, on July 17, 2018, Orgenesis, Inc. reported Weighted Average Number Of Diluted Shares Outstanding of $13,140,119 USD. This represents a change of -27.18% in Weighted Average Number Of Diluted Shares Outstanding.

Period EndPeriodValue
2017-05-31 2017-Q2 9,568,413
2018-05-31 2018-Q2 13,140,119
2016-05-31 2016-Q2 107,583,871,000
2016-08-31 2016-Q3 111,188,616
2017-02-28 2017-Q1 9,285,429
2016-02-29 2016-Q1 103,127,025
2015-08-31 2015-Q3 56,434,465
2015-05-31 2015-Q2 62,795,145
2015-02-28 2015-Q1 56,288,938
2014-08-31 2014-Q3 54,916,980
2014-05-31 2014-Q2 54,010,496
2014-02-28 2014-Q1 52,085,973
2013-08-31 2013-Q3 51,144,621
2013-05-31 2013-Q2 50,032,772
2013-02-28 2013-Q1 49,606,667
2012-08-31 2012-Q3 48,786,381
2012-05-31 2012-Q2 48,557,903
2012-02-29 2012-Q1 69,839,301
2011-08-31 2011-Q3 80,500,000
2011-05-31 2011-Q2 80,500,000
2011-02-28 2011-Q1 80,500,000
2017-08-31 2017-Q3 124,625,412
2018-02-28 2018-Q1 10,775,877
CostOfRevenue DeferredRevenueCurrent GeneralAndAdministrativeExpense IncomeTaxExpenseBenefit IncreaseDecreaseInDeferredRevenue IncreaseDecreaseInPrepaidExpense InterestExpenseShortTermBorrowings OtherNonoperatingIncomeExpense PrepaidExpenseCurrent ResearchAndDevelopmentExpense Revenues ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroMbrFourRynTkMKW ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroNKyFourtrSbNEightcT ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroOnenFivedvBmbCPZerob ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroQJEightQHEightvKrPTQ ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroSixVScnTyThreeEightTNX ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroSrrhxFiveEightxbQlSeven ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroTHSevenFkNTWyFourCJ ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroTwoFivefSixggwbHLHk ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroVpvvmTwoFiveHMcck ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroZpQmcvvcRzmFour ScheduleOfFinancialExpensesZeroThreeEightFourZeroZerohdRbGVtSixGOneWh ScheduleOfFinancialExpensesZeroThreeEightFourZeroZerozHFouryNxKThreeFFourGb ScheduleOfIntangibleAssetsFutureAmortizationExpenseZeroThreeEightFourZeroZeroFourGqHKpPHOnevrG ScheduleOfIntangibleAssetsFutureAmortizationExpenseZeroThreeEightFourZeroZerobTsKmSevenvVKScB ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroFourLMfQFcMBTXZero ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroddPFTwolPmTSixHN ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZerofpdTgJEightdrKRS ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZerolDpQDOneTZeroFMTwoNine ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroshmKPlBDJbtFour ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZerovGLmQlmNSixZerokT ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroxZtEighttqXtPlFV ScheduleOfRevenueZeroThreeEightFourZeroZeroEightNineXwREightzvFiveThreeTd ScheduleOfRevenueZeroThreeEightFourZeroZeroEightwpCFourTwomFFourhgEight ScheduleOfRevenueZeroThreeEightFourZeroZeroKcwVnhZeroNzMtFour ScheduleOfRevenueZeroThreeEightFourZeroZerotttPFiveZRhCOneJr ScheduleOfRevenueZeroThreeEightFourZeroZeroyfmEightcBSMkcgFive ScheduleOfRevenueZeroThreeEightFourZeroZerozMThreeSixFkqmgSsR ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroTJtWLZNZClFk ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroTSevenMKgxCThreeWFourDFour ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroTwoNNinexFivegWDTRsl ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroXlsBMSevenvEightOnenrM ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZerofKFivexOneFiveybTfps ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroxTwoNqFourrgKbJFourThree StockBasedCompensationExpensesRelatedToOptionsGrantedToEmployeesAndDirectors

Related News Stories

Orgenesis, Inc. - Overlooked Stock In The Gene Therapy Contract Development With R&D Pipeline

2018-06-03 seekingalpha
Overlooked specialty contract development and manufacturing stock in the exciting field of advanced cell therapy with a potential for an exponential upside. (184-3)

CUSIP: 68619K105